178 related articles for article (PubMed ID: 17067911)
1. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
Alyea EP; Kim HT; Ho V; Cutler C; DeAngelo DJ; Stone R; Ritz J; Antin JH; Soiffer RJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1047-55. PubMed ID: 17067911
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Pulmonary Toxicity after Total Body Irradiation- and Busulfan-Based Myeloablative Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients.
Liu KX; Poux N; Shin KY; Moore N; Chen YH; Margossian S; Whangbo JS; Duncan CN; Lehmann LE; Marcus KJ
Transplant Cell Ther; 2022 Aug; 28(8):502.e1-502.e12. PubMed ID: 35623615
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion.
Davies JK; Taussig D; Oakervee H; Smith M; Agrawal S; Cavenagh JD; Gribben JG
Br J Haematol; 2013 Aug; 162(4):525-9. PubMed ID: 23718277
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation in follicular lymphoma.
Khouri IF
Best Pract Res Clin Haematol; 2011 Jun; 24(2):271-7. PubMed ID: 21658623
[TBL] [Abstract][Full Text] [Related]
5. Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.
Eapen M; Brazauskas R; Williams DA; Walters MC; St Martin A; Jacobs BL; Antin JH; Bona K; Chaudhury S; Coleman-Cowger VH; DiFronzo NL; Esrick EB; Field JJ; Fitzhugh CD; Kanter J; Kapoor N; Kohn DB; Krishnamurti L; London WB; Pulsipher MA; Talib S; Thompson AA; Waller EK; Wun T; Horowitz MM
J Clin Oncol; 2023 Apr; 41(12):2227-2237. PubMed ID: 36623245
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Harbi S; Brac de la Perriere L; Bouchacourt B; Garciaz S; Pagliardini T; Calmels B; Cecile M; Lefloch AC; Hicheri Y; Hospital MA; Fürst S; Lemarie C; Braticevic C; Legrand F; Bekrieva E; Weiller PJ; Chabannon C; Vey N; Blaise D; Devillier R
Bone Marrow Transplant; 2024 Jan; 59(1):101-106. PubMed ID: 37923831
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of allogeneic hematopoietic stem cell transplantation in advanced age.
Fernandez-Luis S; Gomez Lamas D; Cerezo Martin JM; Mora Barrios JM; Yañez San Segundo L; Sanchez Escamilla M; Fernandez-Escalada N; Calvo Sanchez JA; Fernandez Garcia S; Dominguez-Garcia JJ; Colorado Araujo M; Lopez-Duarte M; Martin-Sanchez G; Insunza Gaminde A; Romon Alonso JI; Lobeira Rubio R; Arroyo Rodriguez JL; Rueda Ciller B; Hermosilla Fernandez M; Marco Betes V; Ocio EM; Bermudez Rodriguez A
Ann Hematol; 2024 Feb; 103(2):583-591. PubMed ID: 37923805
[TBL] [Abstract][Full Text] [Related]
8. Decitabine in combination with idarubicin within a modified busulfan/cyclophosphamide conditioning regimen for patients with advanced myelodysplastic syndrome: A prospective multicenter clinical cohort study.
Cao Y; Wang M; Wang F; Guo W; Ma Y; Li X; He Y; Pang A; Zhang R; Zhai W; Chen X; Ma Q; Wei J; Yang D; Huang Y; Feng D; Liu J; Gao X; Wen S; Wang W; Wang T; Li Y; Fang X; Li Y; Zhang X; Cai Y; Wang Y; Cao W; Lu R; Feng S; Guo R; Fu Y; Du X; Liu Z; Wang X; Wang L; Ma L; Liu C; Zhang X; Han M; Jiang E
Chin Med J (Engl); 2024 May; 137(9):1115-1117. PubMed ID: 38310445
[No Abstract] [Full Text] [Related]
9. Extramedullary relapse following reduced intensity allogeneic hematopoietic cell transplant for adult acute myelogenous leukemia.
Kogut N; Tsai NC; Thomas SH; Palmer J; Paris T; Murata-Collins J; Forman SJ
Leuk Lymphoma; 2013 Mar; 54(3):665-8. PubMed ID: 22906206
[No Abstract] [Full Text] [Related]
10. Molecular alterations monitoring in myelodysplastic patients receiving an allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning regimen.
Robin M; Nibourel O; Tournaire M; Michonneau D; Preudhomme C; Verbanck M; Xhaard A; Adès L; Sicre de Fontbrune F; Sébert M; Fenaux P; Socié G; Peffault de Latour R; Curis E
Bone Marrow Transplant; 2024 May; ():. PubMed ID: 38783124
[No Abstract] [Full Text] [Related]
11. Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity conditioning allogeneic bone marrow transplantation with post-transplantation cyclophosphamide.
Sinanidis I; Hochman MJ; Tsai HL; Randall MP; Bonilla B; Varadhan R; Ambinder AJ; Jones RJ; DeZern AE; Karantanos T
Bone Marrow Transplant; 2024 May; ():. PubMed ID: 38714755
[No Abstract] [Full Text] [Related]
12. High risk of acute pulmonary toxicity with both myeloablative and non-myeloablative total body irradiation-based conditioning for allogeneic stem cell transplantation.
Patel P; Dillon M; Niedzwiecki D; Crowell KA; Horwitz ME; Wang E; Kelsey CR
Bone Marrow Transplant; 2024 Jan; 59(1):150-152. PubMed ID: 37923832
[No Abstract] [Full Text] [Related]
13. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
14. Late Relapse after Allogeneic Stem Cell Transplantation in Patients Treated for Acute Myeloid Leukemia: Relapse Incidence, Characteristics, Role of Conditioning Regimen, and Outcome.
Antier C; Jullien M; Tessoulin B; Loirat M; Peterlin P; Garnier A; Le Bourgeois A; Chevallier P; Guillaume T
Cancers (Basel); 2024 Apr; 16(7):. PubMed ID: 38611097
[TBL] [Abstract][Full Text] [Related]
15. Is Treosulfan-Based Conditioning Attractive as a Reduced-Intensity Conditioning Regimen in Korea?
Kim SH; Ji YS; Yun J; Choi SH; Lim SH; Kim CK; Park SK
J Korean Med Sci; 2023 Sep; 38(36):e281. PubMed ID: 37698206
[TBL] [Abstract][Full Text] [Related]
16. Novel risk assessment for the intensity of conditioning regimen in older patients.
Akahoshi Y; Tada Y; Sakaida E; Kusuda M; Doki N; Uchida N; Fukuda T; Tanaka M; Sawa M; Katayama Y; Matsuoka KI; Ozawa Y; Onizuka M; Kanda J; Kanda Y; Atsuta Y; Nakasone H
Blood Adv; 2023 Sep; 7(17):4738-4747. PubMed ID: 36508283
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic transplantation for advanced acute leukemia.
Weisdorf D
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):534-538. PubMed ID: 36485146
[TBL] [Abstract][Full Text] [Related]
18. The Hematology of Tomorrow Is Here-Preclinical Models Are Not: Cell Therapy for Hematological Malignancies.
Arranz L
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158848
[TBL] [Abstract][Full Text] [Related]
19. Eradication of Measurable Residual Disease in AML: A Challenging Clinical Goal.
Bernasconi P; Borsani O
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34202000
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
